NVP-CGM-097 is a selective inhibitor of mutant forms of the BRAF kinase, particularly the BRAF V600E mutation, which is commonly found in various cancers such as melanoma, non-small cell lung cancer, and colorectal cancer. It is primarily used in research settings to study oncogenic signaling pathways driven by BRAF mutations. Its high selectivity allows for targeted disruption of the MAPK pathway, making it a valuable tool in preclinical studies evaluating resistance mechanisms and combination therapies. It has been investigated in combination with MEK inhibitors to enhance antitumor efficacy and delay the onset of resistance. Due to its pharmacological profile, it supports the development of next-generation BRAF inhibitors with improved activity against resistant tumor variants.